NCT04722068

Regeneron 1331 Kinetics Sub-Study HoFH

A Kinetic Study Investigating Lipoprotein Metabolism Before and After the Administration of REGN1500, an ANGPTL3 Inhibitor, in Patients With Homozygous Familial Hypercholesterolemia. A Sub-study for Subjects Enrolled in the R1500-CL-1331 Clinical Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: University of Pennsylvania · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the lipoprotein kinetics of subjects enrolled in the R1500-CL-1331 clinical trial (NCT02265952) to assess the mechanism by which the evinacumab may affect lipid levels in HoFH subjects.

Detailed description

Subjects enrolled in the R1500-CL-1331 clinical trial (NCT0226595) will participate in a study visit before and after administration of the ANGPTL3 inhibitor REGN1500, evinacumab) for the evaluation of its effect on lipoprotein kinetics.

Conditions

• Hypercholesterolemia, Familial

Interventions

Type	Name	Description
OTHER	Kinetics test	Subjects will participate in two study visits to evaluate lipoprotein kinetics before and after administration of evinacumab.

Timeline

• Start date: 2016-10-07
• Primary completion: 2016-11-30
• Completion: 2021-01-01
• First posted: 2021-01-25
• Last updated: 2021-05-17

Locations

2 sites across 2 countries: United States, Netherlands